PeptidePedia The community reference

Bacterial endotoxin test (revision 18)

Old revision·00:14, 14 May 2025·DiluentDiya

This is an old revision of this page, as it stood at 00:14, 14 May 2025, saved by DiluentDiya with the summary convert the method-comparison paragraph to a table. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Bacterial endotoxin testCompendial test
Also calledLAL test, BET
DetectsLipopolysaccharide from Gram-negative bacterial cell walls
Compendial chapterUSP General Chapter 85
UnitsEndotoxin units per mg or per mL (EU)
Analytical method infobox · conventions

The bacterial endotoxin test detects lipopolysaccharide, a component of the outer membrane of Gram-negative bacteria that provokes a febrile response when introduced parenterally. The test exploits a clotting cascade in amoebocyte lysate derived from horseshoe crab blood, which is activated by picogram quantities of endotoxin.[1]

Endotoxin is not a living organism and is not removed by sterilisation. A preparation can be sterile and pyrogenic at the same time: autoclaving kills bacteria but leaves their lipopolysaccharide intact and biologically active. Endotoxin is the commonest but not the only pyrogen, and a separate rabbit pyrogen test exists for the wider class.[2] This is why endotoxin and sterility are separate determinations answering separate questions.[1]

Results are expressed in endotoxin units, normalised to mass for a drug substance or to volume for a solution. Compendial limits for parenteral products are calculated from the maximum dose, and a research-chemical certificate reporting an endotoxin figure without the basis of normalisation is difficult to interpret.[3]

Methods

[edit]

Three variants are recognised. The gel-clot method observes whether a firm clot forms at a given dilution and gives a limit result rather than a number. The turbidimetric method follows the increase in turbidity as the cascade proceeds and is quantitative. The chromogenic method measures release of a coloured product from a synthetic substrate and is also quantitative.[1]

Recombinant factor C assays, which use a recombinant version of the initiating enzyme rather than crab-derived lysate, have been introduced and are increasingly accepted. They avoid the animal-derived reagent and are more specific, since they respond only to endotoxin and not to β-glucans.

Interference is the routine difficulty. Sample matrices can enhance or inhibit the cascade, so a validated method includes a positive product control demonstrating recovery of a known spike. A result reported without evidence that interference was assessed is not fully interpretable.[1]

Why it matters for peptide material

[edit]

Endotoxin contamination arises from the water and the equipment, not usually from the synthesis. Water is the principal route: bacteria grow readily in stagnant water systems, and even after they are killed their lipopolysaccharide persists. Glassware carries endotoxin unless depyrogenated by dry heat, which is a more aggressive process than sterilisation.[1] Water-system control is accordingly treated as a manufacturing rather than a testing problem.[4]

Lyophilised research peptides are not manufactured as parenteral products and are not required to meet a parenteral endotoxin limit. Some certificates report endotoxin nonetheless; many do not. Absence of the determination is not evidence of a problem, and its presence is not evidence that the material is suitable for any particular purpose.

For comparison, the compendial limit for most parenteral products corresponds to 5 EU per kilogram of body weight per hour, translated into a per-milligram limit by the maximum dose. A figure quoted in EU/mg without the dose basis cannot be compared against that limit by a reader.[3]

See also

References

  1. ^ a b c d e United States Pharmacopeia, General Chapter <85>, Bacterial Endotoxins Test.
  2. ^ United States Pharmacopeia, General Chapter <151>, Pyrogen Test.
  3. ^ a b United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
  4. ^ International Council for Harmonisation, Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000).